Patient
SITE006-0024
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE006 (GBR) (Dr. Rossi)
consented 2025-09-26
Adverse events
7
Serious AEs
3
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 7
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-06-15 (study day 79); relationship: not assessed
Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-27 (study day 60); relationship: not assessed; serious criteria: life-threatening
Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-22 (study day 55); relationship: RELATED; serious criteria: hospitalization
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-05-11 (study day 44); relationship: not assessed
Grade 3 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-05-07 (study day 40); relationship: NOT RELATED; serious criteria: hospitalization
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-05-01 (study day 34); relationship: NOT RELATED
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-03-31 (study day 3); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.